CRISPR Therapeutics names A.J. Silver as new CFO

CRISPR Therapeutics (Nasdaq: CRSP) announced that Raju Prasad, Ph.D., its Chief Financial Officer, is stepping down to pursue external opportunities, with A.J. Silver, the company's Senior Vice President of Finance, taking over as CFO effective Oct. 19, 2026.

Silver has been with CRISPR Therapeutics since October 2018, holding roles across strategic finance, treasury, financial planning and analysis, accounting and reporting, tax, and financial operations. He was named Senior Vice President of Finance in January 2025.

Before joining the company, Silver spent more than 10 years at Ernst & Young LLP, where he became a Certified Public Accountant. He holds a Master of Science in Accounting from the University of Connecticut and a B.S. from Boston College with concentrations in finance and accounting.

Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics, said in a statement that Silver's "deep knowledge of our business combined with his strong operational experience makes him exceptionally well suited to lead us going forward."

Dr. Prasad said he has "decided this is the right time" to take the next step in his career, adding that he remains "confident in the Company's future."

You May Also Be Interested In

• CRISPR Therapeutics Announces Chief Financial Officer Transition
• Ecopetrol names new energy transition VP and two legal officers
• CSL names Deborah Waterhouse as CEO, effective February 2027